StemRIM (TYO:4599)

Japan flag Japan · Delayed Price · Currency is JPY
300.00
+3.00 (1.01%)
At close: Mar 6, 2026
Market Cap18.80B -3.9%
Revenue (ttm)n/a
Net Income-1.90B
EPS-30.56
Shares Out62.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume107,000
Average Volume229,025
Open298.00
Previous Close297.00
Day's Range293.00 - 300.00
52-Week Range246.00 - 370.00
Beta1.02
RSI53.51
Earnings DateMar 11, 2026

About StemRIM

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene thera... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 45
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4599
Full Company Profile

Financial Performance

Financial Statements